ArticleTranslational oncology2026
Mechanistic study of LINC00839-mediated suppression of anoikis in hepatocellular carcinoma via regulation of FOXM1.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the role of LINC00839 in regulating anoikis in hepatocellular carcinoma (HCC) cells. Bioinformatic analysis using UALCAN and Sparkle databases revealed that LINC00839 is highly expressed in HCC tissues and is associated with poor patient prognosis. Functional experiments demonstrated that LINC00839 expression was significantly upregulated in an anoikis model, and its overexpression inhibited apoptosis in HCC cells. This was evidenced by decreased levels of pro-apoptotic proteins Caspase-3 and Bax and increased levels of the anti-apoptotic protein Bcl-2. Transcriptome sequencing and database predictions identified the transcription factor FOXM1 as a key downstream effector. Crucially, siRNA-mediated knockdown of FOXM1 reversed the anti-anoikis effect of LINC00839, confirming its essential role in this pathway. Furthermore, LINC00839 overexpression promoted HCC cell proliferation, migration, and invasion. The study concludes that LINC00839 promotes hepatocellular carcinoma progression by inhibiting anoikis through the upregulation of FOXM1, highlighting its potential as a novel therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.